Tactile Medical Third Quarter 2026 Earnings Conference Call - TACTILE SYSTEMS TECHNOLOGY INC

Explicit Guidance:

• FY2026 Revenue: Maintained at $360–$366 million, representing 9–11% year-over-year growth.
• FY2026 Adjusted EBITDA: Raised to $50–$52 million, representing 12–16% year-over-year growth (vs. $44.8M in FY2025).
• FY2026 Gross Margin: Expected to be approximately 76.5%.
• FY2026 Operating Expenses: Expected to grow 10–12% year-over-year.
• FY2026 Net Interest Income: Projected at approximately $2.4 million.
• FY2026 Effective Tax Rate: Expected to be approximately 28%.
• FY2026 Diluted Shares Outstanding: Approximately 23 million.
• FY2026 Airway Clearance Revenue: Expected to decline mid-to-high single digits year-over-year; sequential improvement anticipated in Q4.
• FY2026 Lymphedema Revenue: Expected to deliver low double-digit growth for the full year; Q4 expected to show meaningful sequential growth with moderated year-over-year growth.

Business-Segment Outlook:

• Lymphedema: Confidence in sustaining low double-digit growth; underlying momentum remains strong despite a higher prior-year comparison in Q4 due to prior NCD alignment benefits. Sequential growth expected in Q4.
• Airway Clearance: Revenue expected to recover sequentially in Q4 as DME customers transition away from excess inventory to next-generation AfloVest systems; no change in underlying patient demand or market leadership.
• Commercial Organization: Introduction of a dedicated strategic accounts team to deepen engagement with IDNs and expand referrals within high-volume accounts; expected to drive strong revenue performance into 2027.
• Sales Force Structure: Plans to activate a territory-splitting playbook involving "territory account managers" and "product specialists" to increase density in high-performing regions; potential consolidation in underperforming territories.
• Operational Efficiency: AI-enabled order management and care navigation reduced medical record review times by ~50%; new Chief Operating Officer (Steve Kiewit) to lead end-to-end order operations and patient services starting immediately.

Market and Competitive Outlook:

• Lymphedema Market: No anticipated slowdown; market remains significantly underpenetrated with ~20 million undiagnosed patients in the U.S.
• Payer Access: Early signs of movement among commercial payers removing "experimental/investigational" designations for FlexiTouch therapy in head and neck cancer-related lymphedema; expected to gradually open access to more eligible patients in 2027.
• Competition/Positioning: AfloVest remains the only untethered, lightest, connected vest; FlexiTouch Pro targeting to reinforce leadership in advanced pneumatic compression.

Macro / Industry Outlook:

• Prior Authorization: Medicare ordering timing disruptions associated with April prior authorization implementation are stabilized; no further material impact expected.
• Reimbursement Pathways: Lymphatec 3D scanner Category 3 CPT code application scheduled for final review at the February 2027 meeting; expected to support wider adoption and earlier diagnosis.
• Regulatory: Full commercialization of Lymphatec 3D scanner monetization model (SAS vs. other) expected later in 2029; current pricing for Lymphatec at academic centers is being validated.

Strategic Initiatives:

• FlexiTouch Pro: 510(k) filed in October 2026; targeting commercial launch in the second half of 2027. Expected to maintain gross margins in line with current FlexiTouch portfolio.
• MyoSleeve: Partnership with Elastomed; focused VA pilot beginning in late Q4 2026 to evaluate clinical fit and go-to-market model before broader U.S. commercialization. Contribution not reflected in 2026 guidance; expected to build gradually.
• Hiring: Steve Kiewit appointed as Chief Operating Officer to unify order operations and patient services.
• Capital Allocation: $12.5 million remaining under $25 million share repurchase program (as of Sept 30, 2026); continued investment in commercial, operational, and strategic capabilities while maintaining operating leverage.

Risks and Headwinds to Outlook:

• Airway Clearance: DME customers are working through existing inventory (Gen 5) longer than anticipated, causing a slower burn rate and temporary revenue decline in Q4; management cannot directly control DME ordering timing.
• Payer Policy Changes: Overcoming restrictive commercial policies for head and neck lymphedema is a gradual "block and tackle" process; revenue impact will be phased rather than a "hockey stick."
• Market Penetration: Large proportion of the 20 million undiagnosed patients requires time for diagnosis and documentation; no automatic sudden influx of patients expected despite new diagnostic tools.
• Investment Timing: Operating expense growth (10–12%) is expected to outpace revenue growth temporarily as investments in technology and sales force annualization mature.

Management Tone on the Future:

• Confidence: High confidence in the durability of the lymphedema business and the "compelling growth model."
• Long-Term View: Emphasis on "durable, sustainable growth" rather than sudden acceleration; 2027 expected to show ongoing leverage and growth as investments return.
• Discipline: Reiteration of commitment to operating leverage, with expectations that OpEx growth will slow relative to revenue as the business scales.
• 2027 Outlook: No specific numerical guidance provided for 2027; management expects continued double-digit lymphedema growth and the introduction of new products (FlexiTouch Pro, MyoSleeve) to support the portfolio, though timing of impact is gradual.

Miscellaneous:

• Non-GAAP Adjustments: FY2026 EBITDA includes adjustments for stock-based compensation ($8.6M), depreciation/amortization ($7.3M), executive transition costs ($1.3M), acquisition-related costs ($3M), and litigation-related costs ($1M).
• Cash Position: Ended Q3 2026 with $75.1 million in cash and $12 million in operating cash flow generated during the quarter.
• FY2027 Capital Efficiency: Management expects to see continued operating leverage in 2027, with revenue growth outpacing operating expense growth as the transformational platform and sales force investments mature.